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significant difference between gp120–cell membrane Gb3
binding and HIV target cell infection. In addition, the known
receptors/co-receptors for gp120 on T cells can be expressed
within the non-DRM fraction and then recruited to detergent
resistant membranes after gp120–viral target cell binding,6 and
so initial binding within the non-detergent resistant mem-
brane fraction does not exclude a later role for cholesterol in
HIV internalization.
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To the Editor: I have read with great interest the article
published recently in your esteemed journal entitled ‘The
Oxford classification of IgA nephropathy: rationale, clinico-
pathologic correlations, and classification’.1 This is a unique
and huge effort by the members of the International IgA
Nephropathy Working Group in trying to standardize the
reporting of pathological criteria of importance in the
prognostication of this most common form of primary
glomerulopathy worldwide.2 I have a few points to make
regarding the nomenclature of this scheme. I understand that
these are conceptual and related to nomenclature, rather than
substantial and related to contents of the study, and that they
merit some consideration by the worthy authors of this
scheme. The points are as follows:
(1) I believe this effort is not the so-called ‘splitters’
approach to classification of diseases, inasmuch as no
artificial classes are defined and the cases are lumped into
these. The approach adopted in this classification is more
akin to the Revised European-American Classification of
Lymphoid Neoplasms (REAL) by the World Health
Organization3 and is much more sensible. As such, its
nomenclature could preferably be changed to ‘consensus
schema’ or ‘formulation’ to truly reflect the unique
endeavor and the methodology adopted in this effort, or
else it could be changed to ‘working classification’ for the
following reasons.
(2) I also assume this is not an end point classification of IgA
nephropathy (IgAN). There is certainly room for
evolution, as the authors also agree in discussion, as
more realistic validation studies are being carried out on
a wide spectrum of cases in routine clinical practice in
different parts of the world. Moreover, the contribution
of immunofluorescence and electron microscopic studies
has not been evaluated in this schema. It will be worth
exploring this aspect of the study of IgAN to see if they
add any value to mere light microscopic scoring of the
renal biopsies adopted in this classification. The future
will definitely see more molecular genetic studies further
refining the crude prognostic criteria that we have at
hand now and true prognostic classes of IgAN may
emerge. Retention of the word ‘classification’ in the
option of nomenclature of ‘working classification’ will
prevent us from repenting in future for not using it,
should this picture emerge in future. This approach has
been successfully adopted by the Banff working classifi-
cation of renal allograft pathology.4
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We thank Dr Muhammed Mubarak1 for his comments
regarding our new classification of immunoglobulin A
nephropathy.2 We agree that optional words could have
been used and were explored. This is why, in part, there are
additional descriptors in the title to help explain what we
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considered was the uniqueness of our approach. We felt that
providing this background, as well as the extensive detailing
of the analytical methods, would strengthen the paper’s
conclusions and would encourage others to use it as a
template for the classification of other kidney diseases. The
approach to the identification of these histological features
is critically important in understanding the classification.3
We agree completely that our classification will change,
but hope this will be by the addition of elements rather than
by its replacement with another classification. We are
currently assessing whether there are additional predictive
features from immunofluorescence and electron microscopy.
We would also agree that in time, genomics, proteomics, and
the development of tissue molecular signatures will have the
potential to provide a new (and ideally better) world of
classification. We also agree that the first step is validation
and this is under way in Europe, Japan, and North America.
However, we do take issue with the suggestion that our
approach follows the format of the Banff criteria developed
for transplant rejection. Their original approach was much
more traditional. They neither collected evidence initially
to inform their subclassification, nor did they demonstrate
reproducibility of the categories or assess the indepen-
dence of specific histological lesions from clinical data in
predicting the outcome.4
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